151 related articles for article (PubMed ID: 36380406)
1. Anti-Platelet Peptides Targeting αIIbβ3 Outside-In Signaling Pathway.
Wang J; Xu X
Curr Protein Pept Sci; 2023; 24(1):31-42. PubMed ID: 36380406
[TBL] [Abstract][Full Text] [Related]
2. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting.
Huang J; Li X; Shi X; Zhu M; Wang J; Huang S; Huang X; Wang H; Li L; Deng H; Zhou Y; Mao J; Long Z; Ma Z; Ye W; Pan J; Xi X; Jin J
J Hematol Oncol; 2019 Mar; 12(1):26. PubMed ID: 30845955
[TBL] [Abstract][Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
4. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
5. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
[TBL] [Abstract][Full Text] [Related]
6. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
7. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
[TBL] [Abstract][Full Text] [Related]
8. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD
J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761
[TBL] [Abstract][Full Text] [Related]
9. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
[TBL] [Abstract][Full Text] [Related]
10. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
11. Integrin αIIbβ3: from discovery to efficacious therapeutic target.
Bledzka K; Smyth SS; Plow EF
Circ Res; 2013 Apr; 112(8):1189-200. PubMed ID: 23580774
[TBL] [Abstract][Full Text] [Related]
12. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Moser M; Bertram U; Peter K; Bode C; Ruef J
J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Lincoff AM; Califf RM; Topol EJ
J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor.
van den Kerkhof DL; Nagy M; Wichapong K; Brouns SLN; Suylen DPL; Hackeng TM; Dijkgraaf I
Thromb Res; 2022 Sep; 217():96-103. PubMed ID: 35926348
[TBL] [Abstract][Full Text] [Related]
16. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
[TBL] [Abstract][Full Text] [Related]
17. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
19. NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis.
Qiao J; Wu X; Luo Q; Wei G; Xu M; Wu Y; Liu Y; Li X; Zi J; Ju W; Fu L; Chen C; Wu Q; Zhu S; Qi K; Li D; Li Z; Andrews RK; Zeng L; Gardiner EE; Xu K
Haematologica; 2018 Sep; 103(9):1568-1576. PubMed ID: 29794149
[TBL] [Abstract][Full Text] [Related]
20. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
